Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Hiroko, Yamada, Taketo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875016/
https://www.ncbi.nlm.nih.gov/pubmed/31781214
http://dx.doi.org/10.1155/2019/6084012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875016/
https://www.ncbi.nlm.nih.gov/pubmed/31781214
http://dx.doi.org/10.1155/2019/6084012

Ejemplares similares